Navigation Links
Zyngenia, Inc. Raises $10 Million in Series A Funding
Date:11/4/2009

ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million in Series A funding from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to create novel, multi-specific antibody-like molecules that address two or more biological targets with a single agent. The company will initially focus on various cancers and autoimmune diseases.

"Zyngenia's technology platform, developed by Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be scientifically, medically, and economically transforming," said Peter Kiener, D.Phil., Zyngenia Chief Executive Officer. "With financial support from NEA, we are poised to take a leadership role in the development of multi-specific biologic therapies."

In previous positions at MedImmune and Bristol-Myers Squibb (BMS), Dr. Kiener gained extensive experience in both biologics and small molecule drug discovery across oncology, immunology, infectious disease and other therapeutic areas. During eight years at MedImmune, most recently as Executive Vice President and Head of Research and Development, Dr. Kiener helped to build industry-leading protein and antibody engineering capabilities and oversaw the submission of numerous INDs and BLAs. Dr. Kiener was also responsible for the integration of both the protein/antibody engineering company Cambridge Antibody Technology and the B-cell biologics company Cellective Therapeutics into MedImmune. Prior to joining MedImmune, Dr. Kiener spent 18 years with Bristol-Myers Squibb's Pharmaceutical Research Division.

Carlos F. Barbas, III, Ph.D., Zyngenia's Chief Scientific Officer, is Professor and Chair of the Skaggs Institut
'/>"/>

SOURCE Zyngenia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... efficiency and data storage may someday run ... polarizations to read and write digital information, ... technology. But ferroelectrics must first overcome a ... habit of "forgetting" stored data. , ... Energy,s Brookhaven National Laboratory have discovered nanoscale ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... 2014 China is increasingly being ... clinical research industry. Clinicaltrial.gov statistics highlight the popularity ... aging population; a high increase in infectious diseases; ... populated pool of patients and a track record ... points, China also presents challenges for the clinical ...
(Date:8/16/2014)... Arlington has received a $229,214 grant from the Walmart ... testing system that would cut the manufacturing costs of ... United States that were formerly built overseas. , The ... announcement of $4 million in awards to seven research ... in Denver made possible through the collaboration between Walmart, ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , The ... , , WASHINGTON, Sept. 16 The Foundation ... national animal research education campaign. Since 2004, public support for humane ... points. The ResearchSaves campaign is designed to counter this drop in ...
... , NEW HAVEN, Conn., Sept. 16 Rib-X ... commercialization of novel drugs for the treatment of multi-antibiotic resistant ... the Company,s Board of Directors, succeeding Joseph Amprey, MD, Ph.D. ... of MedImmune, Chief Executive Officer of AstraZeneca North America, and ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3Biomedical Research Organization Launches Groundbreaking National TV Campaign 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... Scientists at the Houston Methodist Research Institute have figured ... using a pipette -- a common laboratory tool that,s ... preliminary test results in a recent issue of the ... "Studying single cells and their unique functions has become ... faculty member Lidong Qin, Ph.D., the project,s principal investigator. ...
(Date:8/19/2014)... awarded a nearly $40,000 grant from the National Center ... the National Park Service (NPS) and U.S. Department of ... of the energy efficiency and cost effectiveness of radiant ... , Radiant barriers are reflective thermal insulations commonly fitted ... reducing the amount of heat emitted in the direction ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... the release of GeneLinker(TM) Gold and Platinum ... and Proteomics Analysis,Software products.,"The new releases are ... data, a high priority for many of ... Protein Biomarker Package into the,latest versions of ...
... will be brought to the marketplace, giving laboratories ... Technology Transfer GmbH (EMBLEM), the commercial entity of ... that it has signed a licensing deal with ... technology called SPIM (Selective Plane Illumination Microscopy). , ...
... There's a,paradigm in life science and drug development : ... occasions I've,seen very promising drugs candidates or related research ... it, even if millions would have,been saved worldwide. The ... drug candidate that affect a "profitable" disease in addition ...
Cached Biology News:Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
PFK-2 car (P-17)...
... contains 5 ml Dynabeads Epoxy (4.5 m). ... (epoxy) reactive groups. Ideal for coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurring within 16-20 ...
LTBP-2 (7B10)...
... [198C679.2.1] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
Biology Products: